SYRS News and Press, Syros Pharmaceuticals Inc.

2024-07-31 11:10:23 ET Syros Pharmaceuticals, Inc. (SYRS) Q2 2024 Earnings Conference Call July 31, 2024 08:30 AM ET Company Participants Karen Hunady - Director of Investor Relations and Corporate Communications Conley Chee - President and Chief Executive Officer ...

2024-07-31 07:32:02 ET More on Syros Pharmaceuticals Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout Syros Pharmaceuticals, Inc. (SYRS) Q1 2024 Earnings Call Transcript Syros Pharmaceuticals Q2 2024 Earnings Preview Syros ...

-- Pivotal Complete Response (CR) Data from SELECT-MDS-1 Phase 3 Trial Expected by Mid-4Q24 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in September 2024-- -- Management to Host Conference Call at 8:30 AM ET Today -- Syros Pharmaceuticals (NA...

2024-07-30 12:47:29 ET More on Syros Pharmaceuticals Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout Syros Pharmaceuticals, Inc. (SYRS) Q1 2024 Earnings Call Transcript Syros Pharmaceuticals GAAP EPS of -$0.10 beats by $0.77 ...

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, July 31, 2024 to report its s...

2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...

2024-07-17 19:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-02 12:56:55 ET Summary Syros Pharmaceuticals focuses on developing therapies for myeloid cancers. The main pipeline candidate is tamibarotene, with positive signals in phase 2 trial and a key data readout coming in Q4 2024. Financially, SYRS has $112.2 million in asset...

2024-06-18 10:10:00 ET June 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring A...

-- Three medical experts will join members of Syros’ leadership team to provide an overview of HR-MDS patient management, perspectives on the current and future treatment landscape, and the opportunity for tamibarotene on Tuesday, June 25 at 11:00 a.m. ET -- -- Syros expects to rep...